Preda, Carmen M <br/><br/>
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.  [electronic resource] 

 -  United European gastroenterology journal  06 2019 
 - 699-708 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2050-6406 
<br/><br/><label>Standard No.: </label>10.1177/2050640619841254  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>2-Naphthylamine<br/>Aged<br/>Anilides--therapeutic use<br/>Antiviral Agents--therapeutic use<br/>Carbamates--therapeutic use<br/>Carcinoma, Hepatocellular--complications<br/>Chemoembolization, Therapeutic<br/>Cyclopropanes<br/>Hepatectomy<br/>Hepatitis C, Chronic--complications<br/>Humans<br/>Lactams, Macrocyclic<br/>Liver Cirrhosis--complications<br/>Liver Neoplasms--complications<br/>Macrocyclic Compounds--therapeutic use<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Proline--analogs & derivatives<br/>Prospective Studies<br/>Radiofrequency Ablation<br/>Ribavirin--therapeutic use<br/>Ritonavir--therapeutic use<br/>Sulfonamides--therapeutic use<br/>Treatment Outcome<br/>Uracil--analogs & derivatives<br/>Valine